{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T23:03:38Z","timestamp":1768604618173,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Anesth Analg Crit Care"],"DOI":"10.1186\/s44158-025-00324-0","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T03:05:15Z","timestamp":1764817515000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Validation of a predictive risk score of aggressive PK\/PD target non-attainment with continuous infusion piperacillin\/tazobactam or meropenem in critically ill patients having documented Gram-negative infections"],"prefix":"10.1186","volume":"6","author":[{"given":"Milo","family":"Gatti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierantonio","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Siniscalchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Tonetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Pea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"324_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s13054-020-02950-2","volume":"24","author":"M Bauer","year":"2020","unstructured":"Bauer M, Gerlach H, Vogelmann T, Preissing F, Stiefel J, Adam D (2020) Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019- results from a systematic review and meta-analysis. Crit Care 24:239","journal-title":"Crit Care"},{"key":"324_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0140-6736(18)30696-2","volume":"392","author":"M Cecconi","year":"2018","unstructured":"Cecconi M, Evans L, Levy M, Rhodes A (2018) Sepsis and septic shock. Lancet 392:75\u201387","journal-title":"Lancet"},{"key":"324_CR3","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1056\/NEJMra1208623","volume":"369","author":"DC Angus","year":"2013","unstructured":"Angus DC, van der Poll T (2013) Severe sepsis and septic shock. N Engl J Med 369:840\u2013851","journal-title":"N Engl J Med"},{"key":"324_CR4","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","volume":"47","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C et al (2021) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med 47:1181\u20131247","journal-title":"Intensive Care Med"},{"key":"324_CR5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1097\/QCO.0000000000000681","volume":"33","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Portunato F, Roberts JA (2020) Prolonged infusion of beta-lactam antibiotics for gram-negative infections: rationale and evidence base. Curr Opin Infect Dis 33:501\u2013510","journal-title":"Curr Opin Infect Dis"},{"key":"324_CR6","doi-asserted-by":"publisher","first-page":"833189","DOI":"10.3389\/fphar.2022.833189","volume":"13","author":"AV Berry","year":"2022","unstructured":"Berry AV, Kuti JL (2022) Pharmacodynamic thresholds for beta-lactam antibiotics: a story of mouse versus man. Front Pharmacol 13:833189","journal-title":"Front Pharmacol"},{"key":"324_CR7","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s40262-019-00791-z","volume":"58","author":"CD Sumi","year":"2019","unstructured":"Sumi CD, Heffernan AJ, Lipman J, Roberts JA, Sime FB (2019) What antibiotic exposures are required to suppress the emergence of resistance for Gram-negative bacteria? A systematic review. Clin Pharmacokinet 58:1407\u20131443","journal-title":"Clin Pharmacokinet"},{"key":"324_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/14787210.2023.2169131","volume":"21","author":"M Gatti","year":"2023","unstructured":"Gatti M, Pea F (2023) Jumping into the future: overcoming pharmacokinetic\/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-gram-negative infections with novel beta-lactams. Expert Rev Anti-infect Ther 21:149\u2013166","journal-title":"Expert Rev Anti-infect Ther"},{"key":"324_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13054-024-04911-5","volume":"28","author":"M Gatti","year":"2024","unstructured":"Gatti M, Cojutti PG, Pea F (2024) Impact of attaining aggressive vs. conservative PK\/PD target on the clinical efficacy of beta-lactams for the treatment of gram-negative infections in the critically ill patients: a systematic review and meta-analysis. Crit Care 28:123","journal-title":"Crit Care"},{"key":"324_CR10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1186\/s13054-020-03272-z","volume":"24","author":"A Abdulla","year":"2020","unstructured":"Abdulla A, Dijkstra A, Hunfeld NGM, Endeman H, Bahmany S, Ewoldt TMJ et al (2020) Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT). Crit Care 24:558","journal-title":"Crit Care"},{"key":"324_CR11","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","volume":"58","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G et al (2014) DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58:1072\u20131083","journal-title":"Clin Infect Dis"},{"key":"324_CR12","doi-asserted-by":"publisher","first-page":"R126","DOI":"10.1186\/cc9091","volume":"14","author":"FS Taccone","year":"2010","unstructured":"Taccone FS, Laterre P-F, Dugernier T, Spapen H, Delattre I, Wittebole X et al (2010) Insufficient \u03b2-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 14:R126","journal-title":"Crit Care"},{"key":"324_CR13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13054-022-04050-9","volume":"26","author":"M Gatti","year":"2022","unstructured":"Gatti M, Cojutti PG, Bartoletti M, Tonetti T, Bianchini A, Ramirez S et al (2022) Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients. Crit Care 26:178","journal-title":"Crit Care"},{"key":"324_CR14","doi-asserted-by":"publisher","first-page":"106884","DOI":"10.1016\/j.ijantimicag.2023.106884","volume":"62","author":"PG Cojutti","year":"2023","unstructured":"Cojutti PG, Gatti M, Bonifazi F, Caramelli F, Castelli A, Cavo M et al (2023) Impact of a newly established expert clinical pharmacological advice programme based on therapeutic drug monitoring results in tailoring antimicrobial therapy hospital-wide in a tertiary university hospital: findings after the first year of implementation. Int J Antimicrob Agents 62:106884","journal-title":"Int J Antimicrob Agents"},{"key":"324_CR15","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar J-WC, Bassetti M, Bracht H, Dimopoulos G, Marriott D et al (2020) Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med 46:1127\u20131153","journal-title":"Intensive Care Med"},{"key":"324_CR16","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1093\/jac\/dkac291","volume":"77","author":"P Tritscher","year":"2022","unstructured":"Tritscher P, Delannoy M, Agrinier N, Charmillon A, Degand N, Dellamonica J et al (2022) Assessment of current practice for \u03b2-lactam therapeutic drug monitoring in French ICUs in 2021: a nationwide cross-sectional survey. J Antimicrob Chemother 77:2650\u20132657","journal-title":"J Antimicrob Chemother"},{"key":"324_CR17","doi-asserted-by":"crossref","unstructured":"Gatti M, Rinaldi M, Laici C, Bonazzetti C, Vizioli L, Ambretti S et al (2025) Impact of attaining an aggressive PK\/PD target with continuous infusion beta-lactams on the clinical efficacy of targeted therapy of early post-transplant gram-negative infections in critically ill OLT recipients. An interim analysis of a 3-year prospective, observational, study. J Infect Dis jiaf048","DOI":"10.1093\/infdis\/jiaf048"},{"key":"324_CR18","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3390\/antibiotics11040458","volume":"11","author":"G Loeuille","year":"2022","unstructured":"Loeuille G, D\u2019Huart E, Vigneron J, Nisse Y-E, Beiler B, Polo C et al (2022) Stability studies of 16 antibiotics for continuous infusion in intensive care units and for performing outpatient parenteral antimicrobial therapy. Antibiotics 11:458","journal-title":"Antibiotics"},{"key":"324_CR19","doi-asserted-by":"publisher","first-page":"116119","DOI":"10.1016\/j.jpba.2024.116119","volume":"244","author":"S Ramirez","year":"2024","unstructured":"Ramirez S, Scapaticci M, Barbella F, Panico MM, Fecca IA, Cocchini B et al (2024) Development of a rapid LC-MS\/MS method for simultaneous quantification of ten commonly used antibiotic drugs in human serum. J Pharm Biomed Anal 244:116119","journal-title":"J Pharm Biomed Anal"},{"issue":"Suppl 2","key":"324_CR20","doi-asserted-by":"publisher","first-page":"S266","DOI":"10.1093\/clinids\/24.Supplement_2.S266","volume":"24","author":"WA Craig","year":"1997","unstructured":"Craig WA (1997) The pharmacology of meropenem, a new carbapenem antibiotic. Clin Infect Dis 24(Suppl 2):S266-275","journal-title":"Clin Infect Dis"},{"key":"324_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jac\/31.suppl_A.39","volume":"31 Suppl A","author":"F S\u00f6rgel","year":"1993","unstructured":"S\u00f6rgel F, Kinzig M (1993) The chemistry, pharmacokinetics and tissue distribution of piperacillin\/tazobactam. J Antimicrob Chemother 31 Suppl A:39\u201360","journal-title":"J Antimicrob Chemother"},{"key":"324_CR22","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1097\/00003246-199811000-00016","volume":"26","author":"JL Vincent","year":"1998","unstructured":"Vincent JL, de Mendon\u00e7a A, Cantraine F, Moreno R, Takala J, Suter PM et al (1998) Use of the SOFA score to assess the incidence of organ dysfunction\/failure in intensive care units: results of a multicenter, prospective study. Working group on \u201csepsis-related problems\u201d of the European Society of Intensive Care Medicine. Crit Care Med 26:1793\u20131800","journal-title":"Crit Care Med"},{"key":"324_CR23","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/phar.2231","volume":"39","author":"AM Cook","year":"2019","unstructured":"Cook AM, Hatton-Kolpek J (2019) Augmented renal clearance. Pharmacotherapy 39:346\u2013354","journal-title":"Pharmacotherapy"},{"key":"324_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","volume":"36","author":"TC Horan","year":"2008","unstructured":"Horan TC, Andrus M, Dudeck MA (2008) CDC\/NHSN surveillance definition of health care\u2013associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36:309\u2013332","journal-title":"Am J Infect Control"},{"key":"324_CR25","doi-asserted-by":"crossref","unstructured":"Miller JM, Binnicker MJ, Campbell S, Carroll KC, Chapin KC, Gonzalez MD et al (2024) Guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2024 update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clin Infect Dis ciae104","DOI":"10.1093\/cid\/ciae104"},{"key":"324_CR26","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciy381","volume":"67","author":"JM Miller","year":"2018","unstructured":"Miller JM, Binnicker MJ, Campbell S, Carroll KC, Chapin KC, Gilligan PH et al (2018) A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the Infectious Diseases Society of America and the American Society for Microbiologya. Clin Infect Dis 67:e1-94","journal-title":"Clin Infect Dis"},{"key":"324_CR27","doi-asserted-by":"publisher","first-page":"e02497-17","DOI":"10.1128\/AAC.02497-17","volume":"62","author":"RK Shields","year":"2018","unstructured":"Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ (2018) Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother 62:e02497-17","journal-title":"Antimicrob Agents Chemother"},{"key":"324_CR28","doi-asserted-by":"publisher","first-page":"E71","DOI":"10.3390\/antibiotics9020071","volume":"9","author":"A Vena","year":"2020","unstructured":"Vena A, Giacobbe DR, Castaldo N, Cattelan A, Mussini C, Luzzati R et al (2020) Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant gram-negative bacteria other than carbapenem-resistant Enterobacterales. Antibiotics 9:E71","journal-title":"Antibiotics"},{"key":"324_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13054-017-1609-1","volume":"21","author":"H-J De Grooth","year":"2017","unstructured":"De Grooth H-J, Geenen IL, Girbes AR, Vincent J-L, Parienti J-J, Oudemans-van Straaten HM (2017) SOFA and mortality endpoints in randomized controlled trials: a systematic review and meta-regression analysis. Crit Care 21:38","journal-title":"Crit Care"},{"key":"324_CR30","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M et al (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315:801","journal-title":"JAMA"},{"key":"324_CR31","doi-asserted-by":"crossref","unstructured":"Cojutti PG, Pai MP, Tonetti T, Siniscalchi A, Viale P, Pea F (2024) Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin\/tazobactam against extended spectrum beta-lactamase producing Enterobacterales. Leggett JE, editor. Antimicrob Agents Chemother 68:e01404\u201323","DOI":"10.1128\/aac.01404-23"},{"key":"324_CR32","doi-asserted-by":"publisher","first-page":"e0131222","DOI":"10.1128\/aac.01312-22","volume":"67","author":"G An","year":"2023","unstructured":"An G, Creech CB, Wu N, Nation RL, Gu K, Nalbant D et al (2023) Evaluation of empirical dosing regimens for meropenem in intensive care unit patients using population pharmacokinetic modeling and target attainment analysis. Antimicrob Agents Chemother 67:e0131222","journal-title":"Antimicrob Agents Chemother"},{"key":"324_CR33","doi-asserted-by":"crossref","unstructured":"Dickerson RN, Andromalos L, Brown JC, Correia MITD, Pritts W, Ridley EJ et al (2022) Obesity and critical care nutrition: current practice gaps and directions for future research. Crit Care 26. Available from: https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-022-04148-0.\u00a0Cited 2025 Jul 23","DOI":"10.1186\/s13054-022-04148-0"},{"key":"324_CR34","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3390\/pharmaceutics14020445","volume":"14","author":"F Hefny","year":"2022","unstructured":"Hefny F, Stuart A, Kung JY, Mahmoud SH (2022) Prevalence and risk factors of augmented renal clearance: a systematic review and meta-analysis. Pharmaceutics 14:445","journal-title":"Pharmaceutics"},{"key":"324_CR35","doi-asserted-by":"publisher","first-page":"106727","DOI":"10.1016\/j.ijantimicag.2023.106727","volume":"61","author":"MH Alshaer","year":"2023","unstructured":"Alshaer MH, Maranchick N, Alexander KM, Manigaba K, Shoulders BR, Felton TW et al (2023) Beta-lactam target attainment and associated outcomes in patients with bloodstream infections. Int J Antimicrob Agents 61:106727","journal-title":"Int J Antimicrob Agents"},{"key":"324_CR36","doi-asserted-by":"publisher","first-page":"O831","DOI":"10.1111\/1469-0691.12677","volume":"20","author":"Y Harada","year":"2014","unstructured":"Harada Y, Morinaga Y, Kaku N, Nakamura S, Uno N, Hasegawa H et al (2014) In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae. Clin Microbiol Infect 20:O831-839","journal-title":"Clin Microbiol Infect"},{"key":"324_CR37","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.3390\/antibiotics12121717","volume":"12","author":"MV Golikova","year":"2023","unstructured":"Golikova MV, Alieva KN, Strukova EN, Kondratieva DA, Petrova NF, Petrova MA et al (2023) Comparative meropenem pharmacodynamics and emergence of resistance against carbapenem-susceptible non-carbapenemase-producing and carbapenemase-producing Enterobacterales: a pharmacodynamic study in a hollow-fiber infection model. Antibiotics 12:1717","journal-title":"Antibiotics"},{"key":"324_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2017.12.019","volume":"91","author":"PJ Bergen","year":"2018","unstructured":"Bergen PJ, Bulitta JB, Sime FB, Lipman J, McGregor MJ, Millen N et al (2018) Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin\/tazobactam against Pseudomonas aeruginosa and Escherichia coli. Diagn Microbiol Infect Dis 91:69\u201376","journal-title":"Diagn Microbiol Infect Dis"},{"key":"324_CR39","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1128\/AAC.02635-15","volume":"60","author":"RL Soon","year":"2016","unstructured":"Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN et al (2016) Combinatorial pharmacodynamics of ceftolozane-tazobactam against genotypically defined \u03b2-lactamase-producing Escherichia coli: insights into the pharmacokinetics\/pharmacodynamics of \u03b2-lactam\u2013\u03b2-lactamase inhibitor combinations. Antimicrob Agents Chemother 60:1967\u20131973","journal-title":"Antimicrob Agents Chemother"},{"key":"324_CR40","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"R Guilhaumou","year":"2019","unstructured":"Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P et al (2019) Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et R\u00e9animation-SFAR). Crit Care 23:104","journal-title":"Crit Care"}],"container-title":["Journal of Anesthesia, Analgesia and Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44158-025-00324-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s44158-025-00324-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44158-025-00324-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:02:45Z","timestamp":1768564965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s44158-025-00324-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["324"],"URL":"https:\/\/doi.org\/10.1186\/s44158-025-00324-0","relation":{},"ISSN":["2731-3786"],"issn-type":[{"value":"2731-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the local ethical committee (No. 308\/2021\/Oss\/AOUBo on 17 May 2021, No. EM232\u20132022_308\/2021\/Oss\/AOUBo on 16 March 2022, EM449-2023_308\/2021\/Oss\/AOUBo on 17 April 2024). Informed written consent was waived due to the retrospective and observational nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the final version submitted for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.G. received personal fees from Angelini, AdvanzPharma, and Viatris; P.V. has served as a consultant for Biomerieux, Gilead, Merck Sharp & Dohme, Nabriva, Nordic Pharma, Pfizer, Thermo-Fisher and Venatorx, and received payment for serving on the speaker\u2019s bureau for Correvio, Gilead, MerckSharp & Dohme, Nordic Pharma, and Pfizer; F.P. participated in speaker bureau for Angelini, BeiGene, Gilead, InfectoPharm, Menarini, Merck Sharp & Dohme, Pfizer, and Shionogi, and in advisory boards for BeiGene, Merck Sharp & Dohme, Pfizer, and Viatris. The authors report no other conflicts of interest in this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}